Cirugía y Especialidades Médico-Quirúrgicas
Departamento
Hospital de Jerez
Jerez, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Jerez (10)
2021
-
Obstetric Outcomes of SARS-CoV-2 Infection in Asymptomatic Pregnant Women
Viruses, Vol. 13, Núm. 1
-
The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis
BMC Pregnancy and Childbirth, Vol. 21, Núm. 1
2018
-
Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo
Actas Urologicas Espanolas
2015
-
Consensus document on allergic conjunctivitis (DECA)
Journal of Investigational Allergology and Clinical Immunology, Vol. 25, Núm. 2, pp. 94-106
-
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013
European Urology, Vol. 68, Núm. 2, pp. 256-262
-
Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial
European Urology, Vol. 67, Núm. 3, pp. 508-516
2011
2009
-
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203
2008
-
Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
European Urology, Vol. 53, Núm. 5, pp. 992-1002
2005
-
Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial
Journal of Urology, Vol. 174, Núm. 4 I, pp. 1242-1247